To date, approximately 200 different mutations in the MECP2 gene have been identified. We analyzed the entire coding sequence of the MECP2 gene and the X-chromosome inactivation pattern in 42 sporadic cases of Rett syndrome. Of the 42 patients, 30 had pathogenic mutations, including 14 different mutations: 9 missense mutations, 4 nonsense mutations, and 1 frameshift mutation. One was a novel mutation (S134P). There was a tendency for patients who had a nonsense mutation in the transcriptional repression domain region to show earlier onset of regression and more severe language retardation than patients with a mutation in the methyl-CpG binding domain region. However, the parameters of clinical severity were variable among patients with the same type of mutation, depending on the pattern of X-chromosome inactivation. This study suggests that the X-chromosome inactivation pattern can modify the phenotype of Rett syndrome, which is primarily determined by the type and site of MECP2 gene mutation. ( J Child Neurol 2004;19:503—508).
Get full access to this article
View all access options for this article.
References
1.
Percy AK: Rett syndrome. Curr Opin Neurol1995;8:156—160.
2.
Naidu SB: Rett syndrome. Indian J Pediatr1997;64:651—659.
3.
Hagberg B., Aicardi J., Dias K., Ramos O.: A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol1983;14:471—479.
4.
Hagberg B., Hagberg G.: Rett syndrome: Epidemiology and geographical variability. Eur Child Adolesc Psychiatry1997;6(Suppl 1):5—7.
5.
Amir RE, Van den Veyver IB, Wan M., et al: Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet1999 ;23:185—188.
6.
Amano K., Nomura Y., Segawa M., Yamakawa K.: Mutational analysis of the MECP2 gene in Japanese patients with Rett syndrome . J Hum Genet2000;45:231—236.
7.
Amir RE, Van den Veyver IB, Schultz R., et al: Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol2000;47:670—679.
8.
Laccone F., Huppke P., Hanefeld F., Meins M.: Mutation spectrum in patients with Rett syndrome in the German population: Evidence of hot spot regions. Hum Mutat2001 ;17:183—190.
9.
Huppke P., Laccone F., Kramer N., et al: Rett syndrome: Analysis of MECP2 and clinical characterization of 31 patients. Hum Mol Genet2000;9:1369—1375.
10.
Giunti L., Pelagatti S., Lazzerini V., et al.: Spectrum and distribution of MECP2 mutations in 64 Italian Rett syndrome girls: Tentative genotype/phenotype correlation. Brain Dev2001;23(Suppl 1):S242—S245.
11.
Xiang F., Buervenich S., Nicolao P., et al: Mutation screening in Rett syndrome patients. J Med Genet2000;37:250—255.
12.
Cheadle JP, Gill H., Fleming N., et al: Long-read sequence analysis of the MECP2 gene in Rett syndrome patients: Correlation of disease severity with mutation type and location . Hum Mol Genet2000;9:1119—1129.
13.
Bienvenu T. , Villard L., De Roux N., et al: Spectrum of MECP2 mutations in Rett syndrome. Genet Test2002;6(1):1—6.
14.
Bienvenu T. , Carrie A., De Roux N., et al: MECP2 mutations account for most cases of typical forms of Rett syndrome. Hum Mol Genet2000;9:1377—1384.
15.
Chae JH, Hwang YS, Kim KJ: Mutation analysis of MECP2 and clinical characterization in Korean patients with Rett syndrome. J Child Neurol2002;17:33—36.
16.
Diagnostic criteria for Rett syndrome: The Rett Syndrome Diagnostic Criteria Work Group. Ann Neurol1988;23:425—428.
17.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells . Nucleic Acids Res1988;16:12—15.
18.
Kubota T., Nonoyama S., Tonoki H., et al: A new assay for the analysis of X-chromosome inactivation based on methylation-specific PCR. Hum Genet1999 ;104:49—55.
19.
Amir RE, Zoghbi HY: Rett syndrome: Methyl-CpG-binding protein 2 mutations and phenotype-genotype correlations. Am J Med Genet2000;97:147—152.
20.
Xiang F., Buervenich S., Nicolao P., et al: Mutation screening in Rett syndrome patients. J Med Genet2000;37:250—255.
21.
Bourdon V., Philippe C., Labrune O., et al: A detailed analysis of the MECP2 gene: Prevalence of recurrent mutations and gross DNA rearrangements in Rett syndrome patients. Hum Genet2001;108: 43—50.
22.
Wan M., Lee SS, Zhang X., et al: Rett syndrome and beyond: Recurrent spontaneous and familial MECP2 mutations at CpG hotspots. Am J Hum Genet1999;65:1520-1529.
23.
Hoffbuhr KC , Moses LM, Jerdonek MA, et al: Associations between MECP2 mutations, X-chromosome inactivation, and phenotype. Ment Retard Dev Disabil Res Rev2002;8:99—105.
24.
Dragich J., Houwink-Manville I., Schanen C.: Rett syndrome: A surprising result of mutation in MECP2. Hum Mol Genet2000;9: 2365—2375.
25.
Villard L., Kpebe A., Cardoso C., et al: Two affected boys in a Rett syndrome family: Clinical and molecular findings. Neurology2000;55:1188—1193.
26.
Huppke P., Held M., Hanefeld F., et al: Influence of mutation type and location on phenotype in 123 patients with Rett syndrome. Neuropediatrics2002;33:63—68.
27.
Kerr AM, Nomura Y., Armstrong D., et al. Guidelines for reporting clinical features in cases with MECP2 mutations. Brain Dev2001;23:208—211.
28.
Weaving LS, Williamson SL, Bennetts B., et al: Effects of MECP2 mutation type, location and X-inactivation in modulating Rett syndrome phenotype. Am J Med Genet2003;118A:103—114.
